Venus Medtech (Hangzhou) Inc. (Venus Medtech) filed its Monthly Return for Equity Issuer for the period ended 31 March 2026, confirming that both authorised and issued share capital remained unchanged during the month.

• Share Capital Stability – Authorised / registered share capital stood at 441.01 million shares with a par value of RMB 1 each, unchanged from February 2026. – Issued shares totalled 441.01 million H shares and 1,208 unlisted foreign shares, identical to the prior month. No treasury shares were held.

• Public Float Requirement Met – The company affirmed compliance with the Hong Kong Stock Exchange’s 25% minimum public-float threshold as of 31 March 2026.

• Equity Incentive Capacity – No share options were outstanding, granted, exercised or cancelled during March. However, the approved 2023 Share Option Scheme still permits issuance of up to 44.10 million H shares.

• Repurchased but Uncancelled Shares – A total of 3.11 million H shares repurchased in December 2021 remain pending cancellation; no additional share repurchases occurred in March 2026.

• Absence of Dilutive Instruments – The company reported no outstanding warrants, convertible securities or other agreements that could lead to additional share issuance.

With no equity movements recorded in March and ongoing adherence to listing requirements, Venus Medtech’s share structure and public float remain steady ahead of future reporting periods.